Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACSTNASDAQ:NMRANASDAQ:VIGLNASDAQ:VXRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACSTAcasti Pharma$3.11$3.22$1.98▼$3.60$29.23M1.5222,722 shs12,261 shsNMRANeumora Therapeutics$0.70+3.0%$0.78$0.61▼$17.19$113.22M2.961.51 million shs717,663 shsVIGLVigil Neuroscience$7.88-0.1%$2.31$1.31▼$7.95$367.78M1.9642,726 shs2.11 million shsVXRTVaxart$0.46-0.6%$0.40$0.29▼$1.07$105.19M1.272.43 million shs1.23 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACSTAcasti Pharma0.00%0.00%0.00%-7.72%+14.34%NMRANeumora Therapeutics0.00%-1.56%-10.27%-59.05%-92.59%VIGLVigil Neuroscience0.00%+216.87%+340.78%+210.63%+117.36%VXRTVaxart0.00%-7.26%+15.67%-6.38%-46.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACSTAcasti PharmaN/AN/AN/AN/AN/AN/AN/AN/ANMRANeumora Therapeutics2.826 of 5 stars4.11.00.00.01.82.51.3VIGLVigil Neuroscience3.5812 of 5 stars4.05.00.00.02.42.50.6VXRTVaxart2.6946 of 5 stars3.53.00.00.03.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACSTAcasti Pharma 3.00Buy$10.00221.54% UpsideNMRANeumora Therapeutics 2.22Hold$9.291,226.53% UpsideVIGLVigil Neuroscience 2.00Hold$11.5045.94% UpsideVXRTVaxart 3.00Buy$3.00550.90% UpsideCurrent Analyst Ratings BreakdownLatest ACST, VIGL, VXRT, and NMRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025VIGLVigil NeuroscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$14.00 ➝ $8.005/23/2025VIGLVigil NeuroscienceMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025VIGLVigil NeuroscienceJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold5/22/2025VIGLVigil NeuroscienceGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Neutral$8.005/22/2025VIGLVigil NeuroscienceCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform5/22/2025VIGLVigil NeuroscienceGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025VIGLVigil NeuroscienceCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025VIGLVigil NeuroscienceJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform5/22/2025VIGLVigil NeuroscienceWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$13.00 ➝ $8.005/22/2025VIGLVigil NeuroscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2025NMRANeumora TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACSTAcasti PharmaN/AN/AN/AN/A$6.57 per shareN/ANMRANeumora TherapeuticsN/AN/AN/AN/A$3.07 per shareN/AVIGLVigil NeuroscienceN/AN/AN/AN/A$3.24 per shareN/AVXRTVaxart$47.40M2.22N/AN/A$0.38 per share1.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACSTAcasti Pharma-$12.85M-$1.44N/AN/AN/AN/A-13.61%-11.56%N/ANMRANeumora Therapeutics-$235.93M-$1.61N/AN/AN/AN/A-73.63%-68.97%8/5/2025 (Estimated)VIGLVigil Neuroscience-$82.64M-$2.05N/AN/AN/AN/A-83.89%-65.34%8/12/2025 (Estimated)VXRTVaxart-$82.46M-$0.27N/AN/AN/A-431.61%-110.46%-62.78%8/14/2025 (Estimated)Latest ACST, VIGL, VXRT, and NMRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025VXRTVaxart-$0.07-$0.07N/A-$0.07$2.85 million$20.88 million5/12/2025Q1 2025NMRANeumora Therapeutics-$0.40-$0.42-$0.02-$0.42N/AN/A5/7/2025Q1 2025VIGLVigil Neuroscience-$0.53-$0.49+$0.04-$0.49N/AN/A3/20/2025Q4 2024VXRTVaxart-$0.10-$0.05+$0.05-$0.05$15.68 million$15.19 million3/13/2025Q4 2024VIGLVigil Neuroscience-$0.49-$0.57-$0.08-$0.57N/AN/A3/6/2025Q4 2024NMRANeumora Therapeutics-$0.46-$0.37+$0.09-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACSTAcasti PharmaN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/AVIGLVigil NeuroscienceN/AN/AN/AN/AN/AVXRTVaxartN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACSTAcasti PharmaN/A7.867.86NMRANeumora TherapeuticsN/A10.9810.98VIGLVigil NeuroscienceN/A3.723.72VXRTVaxartN/A0.830.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACSTAcasti Pharma6.08%NMRANeumora Therapeutics47.65%VIGLVigil Neuroscience83.64%VXRTVaxart18.05%Insider OwnershipCompanyInsider OwnershipACSTAcasti Pharma13.51%NMRANeumora Therapeutics26.80%VIGLVigil Neuroscience18.01%VXRTVaxart2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACSTAcasti Pharma329.40 million8.77 millionNot OptionableNMRANeumora Therapeutics108161.75 million118.91 millionOptionableVIGLVigil Neuroscience4046.67 million27.38 millionNot OptionableVXRTVaxart120228.22 million221.57 millionOptionableACST, VIGL, VXRT, and NMRA HeadlinesRecent News About These CompaniesVaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 TrialMay 27 at 8:00 AM | globenewswire.comVaxart (NASDAQ:VXRT) Raised to Hold at Wall Street ZenMay 25 at 3:39 AM | americanbankingnews.comWall Street Zen Upgrades Vaxart (NASDAQ:VXRT) to "Hold"May 24 at 11:33 AM | marketbeat.comVaxart Announces Adjournment of Annual Meeting of StockholdersMay 21, 2025 | globenewswire.comVaxart, Inc. Grants Equity Awards to New CFO Jeroen GrasmanMay 20, 2025 | quiverquant.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VXRT Stock NewsMay 20, 2025 | gurufocus.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 20, 2025 | globenewswire.comVaxart, Inc. (NASDAQ:VXRT) Insider Steven Lo Acquires 100,000 SharesMay 20, 2025 | insidertrades.comVaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder MeetingMay 16, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Shares Pass Below 200-Day Moving Average - Here's What HappenedMay 16, 2025 | marketbeat.comVaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 TrialMay 15, 2025 | globenewswire.comVaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational MedicineMay 14, 2025 | globenewswire.comVaxart Names Grasman as CFO, Succeeding LeeMay 14, 2025 | marketwatch.comVaxart, Inc. (VXRT) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comVaxart Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comVaxart Appoints Jeroen Grasman as Chief Financial OfficerMay 13, 2025 | globenewswire.comVaxart Proposes Reverse Stock Split to Avoid DelistingMay 12, 2025 | tipranks.comVaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy StatementMay 12, 2025 | globenewswire.comVaxart (VXRT) Projected to Post Quarterly Earnings on MondayMay 7, 2025 | marketbeat.comVaxart Resumes COVID-19 Vaccine Trial After Government LiftMay 5, 2025 | tipranks.comVaxart CEO Issues Letter to Stockholders Highlighting Company ProgressMay 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACST, VIGL, VXRT, and NMRA Company DescriptionsAcasti Pharma NASDAQ:ACSTAcasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.Neumora Therapeutics NASDAQ:NMRA$0.70 +0.02 (+2.99%) Closing price 04:00 PM EasternExtended Trading$0.69 -0.01 (-1.86%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.Vigil Neuroscience NASDAQ:VIGL$7.88 -0.01 (-0.13%) Closing price 04:00 PM EasternExtended Trading$7.88 0.00 (-0.06%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.Vaxart NASDAQ:VXRT$0.46 0.00 (-0.56%) Closing price 04:00 PM EasternExtended Trading$0.47 +0.01 (+1.32%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
